To facilitate clinical implementation of pharmacogenomics to predict cancer-treatment-related cardiotoxicity, future research efforts should aim to expand comparable approaches to other candidate SNPs as well as additional treatments such as checkpoint inhibitors and CDK4/6 inhibitors, and to include additional acute and chronic cardiotoxicity risk factors with the aim of creating a comprehensive baseline risk assessment. Here, CDK4 is linked to cancer.